Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- 28 December 2015
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 27 (4), 559-574
- https://doi.org/10.1093/annonc/mdv623
Abstract
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers. Therefore, their use will not be limited anymore to selected hospitals involved in clinical trials. Indeed, they will be routinely prescribed in many cancer centers across the world. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events (irAEs). This new family of dysimmune toxicities remains largely unknown to the broad oncology community. Although severe irAEs remain rare (∼10% of cases under monotherapy), they can become life-threatening if not anticipated and managed appropriately. Over the last 5 years, Gustave Roussy has accumulated a significant experience in the prescription of immune checkpoint blockade (ICB) antibodies and the management of their toxicities. Together with the collaboration of Gustave Roussy's network of organ specialists with expertise in irAEs, we propose here some practical guidelines for the oncologist to help in the clinical care of patients under ICB immunotherapy.Keywords
This publication has 84 references indexed in Scilit:
- Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsisCritical Care, 2014
- The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysisJournal of the American Academy of Dermatology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanomaExperimental Hematology & Oncology, 2012
- Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic MelanomaDigestive Diseases and Sciences, 2012
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnnals of Oncology, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)Journal of Immunotherapy, 2009
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy, 2004
- Immune Reconstitution Inflammatory SyndromeMedicine, 2002